Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Moves On From Selonsertib, Looks To ATLAS To Map Its NASH Future

Executive Summary

Gilead detailed its Phase III failure with ASK1 inhibitor selonsertib in NASH, but anticipates finding a new regimen to take into Phase III in NASH with the ATLAS combination study data expected in December.

You may also be interested in...



Alnylam Interview: RNAi Leader Expands Into NASH, CNS And Eye Diseases

Feature article: Alnylam’s R&D leader Akshay Vaishnaw sets out plans for next-generation gene-silencing therapies.

Intercept Says Data Indicate Pruritus Worries In NASH Could Be Overstated

Patient-reported outcomes indicate patients don’t see itch as a major quality-of-life factor. Intercept also reports that adding earlier-stage patients to review of OCA shows better data on resolving NASH.

Gilead Increasingly Seems Focused On Combo Therapy In NASH

At EASL, Gilead indicated it may not take any of its current NASH candidates forward as monotherapy options. Trial collaboration with Novo Nordisk may suggest pessimism toward selonsertib after Phase III disappointment.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC126183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel